Atavistik Bio is restoring protein function in disease with innovative approaches.

Atavistik Bio’s high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable us to discover first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control.
-
Industry
-
Milestones
- Lux investment: 2021
-
Founders
- Jared Rutter, PhD
- Ralph J DeBerardinis, MD, PhD
LUX Partners